AlloVir Inc.

2.06+0.0050+0.24%Vol 526.90K1Y Perf -76.60%
Oct 4th, 2023 15:52 DELAYED
BID2.05 ASK2.06
Open2.05 Previous Close2.05
Pre-Market- After-Market-
 - -%  - -
Target Price
26.25 
Analyst Rating
Strong Buy 1.00
Potential %
1.16K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-79/-93 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-82/-97 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-87/-94 
Income Ranking
 —    -
Price Range Ratio 52W %
1.85 
Earnings Rating
Market Cap234.00M 
Earnings Date
2nd Nov 2023
Alpha-0.04 Standard Deviation0.23
Beta0.78 

Today's Price Range

1.952.08

52W Range

1.9010.29

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-7.66%
1 Month
-36.34%
3 Months
-36.73%
6 Months
-46.05%
1 Year
-76.60%
3 Years
-92.74%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALVR2.060.00500.24
AAPL173.681.28200.74
GOOG136.313.01002.26
MSFT319.736.34002.02
XOM111.46-4.3700-3.77
WFC38.940.26500.69
JNJ155.580.24000.15
FB196.640.99000.51
GE108.781.02000.95
JPM143.210.50000.35
Financial StrengthValueIndustryS&P 500US Markets
12.80
13.10
0.07
0.09
-
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.45-0.48-6.67
Q01 2023-0.47-0.446.38
Q04 2022-0.51-0.3727.45
Q03 2022-0.52-0.503.85
Q02 2022-0.70-0.691.43
Q01 2022-0.74-0.696.76
Q04 2021-0.71-0.92-29.58
Q03 2021-0.59-0.72-22.03
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date2nd Nov 2023
Estimated EPS Next Report-0.42
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume526.90K
Shares Outstanding113.87K
Shares Float49.86M
Trades Count4.02K
Dollar Volume1.06M
Avg. Volume823.52K
Avg. Weekly Volume635.93K
Avg. Monthly Volume1.01M
Avg. Quarterly Volume823.81K

AlloVir Inc. (NASDAQ: ALVR) stock closed at 2.05 per share at the end of the most recent trading day (a 3.02% change compared to the prior day closing price) with a volume of 643.81K shares and market capitalization of 234.00M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. AlloVir Inc. CEO is David Hallal.

The one-year performance of AlloVir Inc. stock is -76.6%, while year-to-date (YTD) performance is -60.04%. ALVR stock has a five-year performance of %. Its 52-week range is between 1.9 and 10.29, which gives ALVR stock a 52-week price range ratio of 1.85%

AlloVir Inc. currently has a PE ratio of -1.80, a price-to-book (PB) ratio of 1.89, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -61.79%, a ROC of -65.96% and a ROE of -72.43%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from AlloVir Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.42 for the next earnings report. AlloVir Inc.’s next earnings report date is 02nd Nov 2023.

The consensus rating of Wall Street analysts for AlloVir Inc. is Strong Buy (1), with a target price of $26.25, which is +1 162.02% compared to the current price. The earnings rating for AlloVir Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AlloVir Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AlloVir Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.21, ATR14 : 0.23, CCI20 : -101.74, Chaikin Money Flow : -0.05, MACD : -0.24, Money Flow Index : 40.46, ROC : -18.33, RSI : 34.00, STOCH (14,3) : 17.44, STOCH RSI : 0.33, UO : 41.99, Williams %R : -82.56), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AlloVir Inc. in the last 12-months were: Brainard Diana (Sold 81 534 shares of value $344 668 ), Brett R. Hagen (Sold 40 616 shares of value $325 910 ), Diana Brainard (Sold 44 072 shares of value $241 596 ), Diana M. Brainard (Sold 52 480 shares of value $272 779 ), Edward Miller (Sold 6 037 shares of value $44 472 ), Ercem Atillasoy (Sold 4 190 shares of value $36 545 ), GILEAD SCIENCES, INC. (Buy at a value of $10 990 762), Hagen Brett (Sold 7 637 shares of value $40 659 ), Hagen Brett R (Sold 5 729 shares of value $30 816 ), Jeroen B. Van Beek (Sold 68 214 shares of value $547 757 ), Sciences Inc Gilead (Buy at a value of $10 990 762), Sinha Vikas (Sold 5 618 shares of value $18 161 ), Vikas Sinha (Sold 32 069 shares of value $156 947 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

AlloVir Inc.

AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.

CEO: David Hallal

Telephone: +1 617 433-2605

Address: 139 Main Street, Cambridge 02142, MA, US

Number of employees: 53

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

61%39%

Bearish Bullish

63%37%

 

News

Stocktwits